A novel targeted alpha-particle therapy (TAT), 225Ac-MTI-201, targets the melanocortin 1 receptor (MC1R) which is highly expressed in metastatic uveal melanoma (MUM) and is currently in a first-in-human clinical trial. The favorable qualities of TAT include t...
Mark L. McLaughlin, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine